Skip to content

Effect of honey on type 2 diabetes

Effect of honey consumption on the lipid profile, blood pressure, and serum levels of adiponectin and C-reactive protein in patients with type 2 diabetes

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015062122364N2
Enrollment
50
Registered
2015-08-04
Start date
2015-04-14
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: The intervention group consume Astragalus honey ( 50 grams per day) three times between meals for 8 weeks.After wash out period(4 weeks) , they will not consume honey(8 weeks.). Interv
The intervention group consume Astragalus honey ( 50 grams per day) three times between meals for 8 weeks.After wash out period(4 weeks) , they will not consume honey(8 weeks.)
Control group do not consume honey.After wash out period, they will consume honey for 8 weeks.

Sponsors

Vice Chancellor for research of Shiraz University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: type II diabetic patient with a fasting blood sugar less than 200 milligrams per deciliter; free of a history or presence of malignancy; acute and emergency states; a history of major operations; a drug history of Immunomodulators, cytotoxic or immunosuppressive agents; no pregnancy or lactation if female; and not using insulin for diabetes control. Exclusion criteria: Participants will exclude in the case of any kind of acute diseases; hospitalization or meet the criteria mentioned in Inclusion criteria.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Adiponectin. Timepoint: Baseline, 8 weeks after baseline, the end of the washout period, 8 weeks after the start of the second period. Method of measurement: ELISA.;C-reactive protein. Timepoint: Baseline, 8 weeks after baseline, the end of the washout period, 8 weeks after the start of the second period. Method of measurement: ELISA.

Secondary

MeasureTime frame
Total cholestrol. Timepoint: Baseline, 8 weeks after baseline, the end of the washout period , 8 weeks after the start of the second period of study. Method of measurement: Pars Azmun Kit.;Triglyceride. Timepoint: Baseline, 8 weeks after baseline, the end of the washout period , 8 weeks after the start of the second period of study. Method of measurement: Pars Azmun Kit.;LDL cholestrol. Timepoint: Baseline, 8 weeks after baseline, the end of the washout period , 8 weeks after the start of the second period of study. Method of measurement: Pars Azmun Kit.;HDL cholestrol. Timepoint: Baseline, 8 weeks after baseline, the end of the washout period , 8 weeks after the start of the second period of study. Method of measurement: Pars Azmun Kit.;Blood pressure. Timepoint: Baseline, 4 weeks after baseline, 8 weeks after baseline, the end of the washout period, 4 weeks after the start of the second period of study , 8 weeks after the start of the second period of study. Method of measurement: mercury manometer.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Masoume Akhlaghi

Shiraz University of Medical Science

msm.akhlaghi@gmail.com+98 71 3725 1001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026